Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Abstract
Summary: Context Sunitinib malate is an oral tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumours. Hypothyroidism has been observed in patients treated with sunitinib, but the mechanism whereby sunitinib induces hypothyroidism is unknown. Objective To describe a series of six patients who developed thyrotoxicosis while on sunitinib for metastatic RCC. Setting The study was conducted at Austin Health, a tertiary teaching hospital in Melbourne, Australia. Results Two patients developed severe thyrotoxicosis within 10 weeks after commencing sunitinib. In contrast, in the four patients who presented with later onset (16–30 weeks) thyrotoxicosis, the thyrotoxicosis was relatively mild, self‐limiting and rapidly progressed to hypothyroidism. These patients experienced recurrent episodes of thyrotoxicosis in temporal relation to their cyclical sunitinib treatment. One patient had cytological evidence of lymphocytic thyroiditis. Conclusions These findings suggest that sunitinib‐induced hypothyroidism may be a consequence of preceding thyroiditis with associated transient thyrotoxicosis. As predictive factors are currently unknown, we suggest regular monitoring of thyroid function in all patients commenced on sunitinib. Clinicians treating patients with sunitinib or other similar kinase inhibitors should to be alerted to thyroid dysfunction as a potential toxicity of these agents.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Another study found that 6 of 31 (19.3%) receiving sunitinib therapy for metastatic renal cell carcinoma developed thyrotoxicosis, including one case of thyroid storm.
“Another study found that 6 of 31 (19.3%)receiving sunitinib therapy for metastatic renal cell carcinoma developed thyrotoxicosis, including one case of thyroid storm (644).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [644]
Cites
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O’Brien, S., Davis, R. B., Gowen, L. C., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 773 · see citing works
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., Morgan, J. A., Dychter, S. S., Larsen, P. R., Demetri, G. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00008 · Cited by 402 · see citing works
Self-citationHypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Rini, B. I., Tamaskar, I., Shaheen, P., Salas, R. N., Garcia, J., Wood, L. S., Reddy, S. S. K., Dreicer, R., & Bukowski, R. M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk008 · Cited by 378 · see citing works
Mannavola, D., Coco, P., Vannucchi, G. M., Bertulli, R., Carletto, M., Casali, P. G., Beck‐Peccoz, P., & Fugazzola, L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0586 · Cited by 227 · see citing works
Wong, E., Rosen, L. S., Mulay, M., VanVugt, A., Dinolfo, M., Tomoda, C., Sugawara, M., & Hershman, J. M. (2007) · Thyroid · doi:10.1089/thy.2006.0308 · Cited by 206 · see citing works
The clinical and physiological spectrum of interferon‐alpha induced thyroiditis
Mandac, J. C., Chaudhry, S., Sherman, K. E., & Tomer, Y. (2006) · Hepatology · doi:10.1002/hep.21146 · Cited by 193 · see citing works
Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function
Jf, W., Milosveski, V., Schramek, C., Fong, G. H., Becks, G. P., & Hill, D. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1570005 · Cited by 97 · see citing works
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
Schöffski, P., Dumez, H., Clément, P. M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj133 · Cited by 91 · see citing works
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
Badros, A. Z., Siegel, E., Bodenner, D., Zangari, M., Zeldis, J., Barlogie, B., & Tricot, G. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01137-8 · Cited by 83 · see citing works
Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer
Santoro, M., & Carlomagno, F. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0073 · Cited by 81 · see citing works
Transformation of thyroid epithelium is associated with loss of c-kit receptor.
Natali, P. G., Berlingieri, M. T., Nicotra, M. R., et al. (1995) · PubMed · Cited by 81 · see citing works
Wolter, P., Dumez, H., & Schöffski, P. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070327 · Cited by 48 · see citing works
Stein, E. M., & Rivera, C. (2007) · Thyroid · doi:10.1089/thy.2006.0294 · Cited by 26 · see citing works
Desai, J., Gurney, H., Pavlakis, N., et al. (2007) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2007.00136.x · Cited by 16 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938 · see citing works
Drugs affecting thyroid function
Barbesino, G. (2010) · Thyroid · doi:10.1089/thy.2010.1635 · Cited by 146 · see citing works
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
Abdulrahman, R. M., Verloop, H., Hoftijzer, H., Verburg, E., Hovens, G. C., Corssmit, E. P., Reiners, C., Gelderblom, H., Pereira, A. M., Kapiteijn, E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2507 · Cited by 112 · see citing works
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
Illouz, F., Laboureau-Soares, S., Dubois, S., Rohmer, V., & Rodien, P. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0648 · Cited by 77 · see citing works
Thyroid dysfunctions induced by tyrosine kinase inhibitors
Fallahi, P., Ferrari, S. M., Vita, R., Di Domenicantonio, A., Corrado, A., Benvenga, S., & Antonelli, A. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.913021 · Cited by 60 · see citing works
Miyake, H., Kurahashi, T., Yamanaka, K., Kondo, Y., Muramaki, M., Takenaka, A., Inoue, T.-A., & Fujisawa, M. (2010) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.08.011 · Cited by 54 · see citing works
Drugs and Other Substances Interfering with Thyroid Function
Montanelli, L., Benvenga, S., Hegedüs, L., Vitti, P., Latrofa, F., & Duntas, L. H. (2018) · Endocrinology · doi:10.1007/978-3-319-45013-1_27 · Cited by 18 · see citing works
- Authors
- Grossmann, M., Premaratne, E., Desai, J., & Davis, I. D.
- Affiliations
- Austin Hospital (AU)
- The Royal Melbourne Hospital (AU)
- Corresponding author
- Davis, Ian D.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2008-09-10
- Volume
- 69
- Issue
- 4
- Pages
- 669-672
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2028104544
- Cited by
- 109
- References
- 14
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 6 · 2015: 8 · 2014: 8 · 2013: 7 · 2012: 10
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- sunitinib, thyrotoxicosis, hypothyroidism, renal cell carcinoma, tyrosine kinase inhibitors, drug-induced thyroid dysfunction, lymphocytic thyroiditis, thyroid function monitoring, adverse drug reactions
- MeSH terms
- Sunitinib, Adult, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Thyrotoxicosis, Thyrotropin, Thyroxine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
